Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Files to Start Trial of Bacterial Vaccine

publication date: Jan 31, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech submitted a request to the SFDA to conduct a clinical trial of its newly developed 23-valent and 24-valent pneumococcal polysaccharides vaccines (PPV). The vaccines are designed to protect against pneumonia, meningitis and febrile bacteremia along with sinusitis and bronchitis. The target populations are children over the age of two and adults, especially those older than 65 and those with long-term health problems. More details....

Stock Symbol: (NSDQ: SVA)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors